Arora D, Mudgal J, Nampoothiri M, Mallik S, Kinra M, Hall S
Metab Brain Dis. 2018; 33(4):1045-1051.
PMID: 29516413
DOI: 10.1007/s11011-018-0201-y.
Tarazi F
J Sci Res Med Sci. 2013; 3(2):93-104.
PMID: 24019715
PMC: 3174705.
Chen Y, Xu X, Liu X, Yu M, Liu B, Zhang G
PLoS One. 2012; 7(4):e35186.
PMID: 22558126
PMC: 3340383.
DOI: 10.1371/journal.pone.0035186.
Gunes A, Dahl M, Spina E, Scordo M
Eur J Clin Pharmacol. 2008; 64(5):477-82.
PMID: 18205001
DOI: 10.1007/s00228-007-0450-x.
Fasulo W, Hemby S
J Neurochem. 2003; 87(1):205-19.
PMID: 12969267
PMC: 3843351.
DOI: 10.1046/j.1471-4159.2003.01986.x.
Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
Abekawa T, Honda M, Ito K, Koyama T
Psychopharmacology (Berl). 2003; 169(3-4):247-56.
PMID: 12898123
DOI: 10.1007/s00213-003-1517-8.
Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
Andersen H, Kilpatrick I
Br J Pharmacol. 1996; 118(2):421-7.
PMID: 8735647
PMC: 1909633.
DOI: 10.1111/j.1476-5381.1996.tb15419.x.
A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.
Singh A, Barlas C, Singh S, Franks P, Mishra R
J Psychiatry Neurosci. 1996; 21(1):29-35.
PMID: 8580115
PMC: 1188731.
Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.
Dunn L, Atwater G, Kilts C
Psychopharmacology (Berl). 1993; 112(2-3):315-23.
PMID: 7871036
DOI: 10.1007/BF02244927.
Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol.
Rebec G, Peirson E, McPherson F, Brugge K
Psychopharmacology (Berl). 1982; 77(4):360-6.
PMID: 6813898
DOI: 10.1007/BF00432771.
Chronic benztropine and haloperidol administration induce behaviorally equivalent pharmacological hypersensitivities separately but not in combination.
Carey R
Psychopharmacology (Berl). 1982; 76(4):341-5.
PMID: 6812108
DOI: 10.1007/BF00449122.
Treatment schedule as a determinant of the development of tolerance to haloperidol.
Carey R
Psychopharmacology (Berl). 1984; 82(3):164-7.
PMID: 6425895
DOI: 10.1007/BF00427766.
Gnawing and changes in reactivity produced by microinjections of picrotoxin into the superior colliculus of rats.
Redgrave P, Dean P, Souki W, Lewis G
Psychopharmacology (Berl). 1981; 75(2):198-203.
PMID: 6275443
DOI: 10.1007/BF00432187.
Tardive dyskinesia.
Br Med J (Clin Res Ed). 1981; 282(6272):1257-8.
PMID: 6112037
PMC: 1505392.
Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum.
Kelley A, Lang C, Gauthier A
Psychopharmacology (Berl). 1988; 95(4):556-9.
PMID: 3145527
DOI: 10.1007/BF00172976.
The negative symptoms of schizophrenia and the monoamine oxidase inhibitors.
Bucci L
Psychopharmacology (Berl). 1987; 91(1):104-8.
PMID: 3103152
DOI: 10.1007/BF00690936.
Differential distribution of biogenic amines in the hypoglossal nucleus of the rat.
Aldes L, Chronister R, Marco L, Haycock J, Thibault J
Exp Brain Res. 1988; 73(2):305-14.
PMID: 2905674
DOI: 10.1007/BF00248222.
Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission.
McMILLEN B
J Neural Transm. 1985; 64(1):1-12.
PMID: 2866230
DOI: 10.1007/BF01259341.
Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity.
Kelley A, Bakshi V, Delfs J, Lang C
Psychopharmacology (Berl). 1989; 99(4):542-9.
PMID: 2594921
DOI: 10.1007/BF00589906.
Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
Kinon B, Kane J
Psychopharmacology (Berl). 1989; 98(4):465-71.
PMID: 2505286
DOI: 10.1007/BF00441943.
